Addition of the PCSK9 inhibitor evolocumab to statin therapy after CABG surgery does not improve 24-month graft patency, in ...

Although CABG remains the revascularization treatment of choice for patients with severely symptomatic or life-threatening coronary artery disease (CAD), 9% to 25% of the patients who have undergone ...

Among over 1.2 million patients who underwent primary isolated CABG from 2011 to 2020, women had a higher unadjusted operative mortality versus men (2.8% vs 1.7%, P<0.001), as well as a higher overall ...

Please provide your email address to receive an email when new articles are posted on . Intraoperative transesophageal echocardiography during CABG was associated with lower odds of 30-day mortality, ...

Bypass surgery is a type of open-heart surgery. Surgeons may use several different types of bypass surgeries to repair or replace the heart. Open-heart surgery is an operation where surgeons repair or ...

Researchers report there has been a decline of roughly 36 percent in the number of patients undergoing a CABG; but reassuringly, the risk of death and other poor outcomes remains identical among those ...

MADRID, Spain—Adding evolocumab (Repatha; Amgen) to statin therapy does not lower the risk of saphenous vein graft (SVG) failure among patients who undergo coronary artery bypass surgery, the ...

New York, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "BRIC Cardiovascular Surgery Procedures Outlook to 2025 - Coronary Artery Bypass Graft (CABG) ...